Latest Healthcare Research Reports

Tag: Johnson & Johnson

  • Genitourinary Drugs Industry Forecast to Hit $34.76 Billion by 2029 With a Strong 2.9% CAGR

    Genitourinary Drugs Industry Forecast to Hit $34.76 Billion by 2029 With a Strong 2.9% CAGR

    Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

    #What Are The Current (2025) And Forecast (2029) Sizes Of The Genitourinary Drugs Market?

    The genitourinary drugs market size has shown steady expansion in recent years. It is anticipated to increase from $30.07 billion in 2024 to $31.02 billion in 2025, achieving a compound annual growth rate (CAGR) of 3.2%. This past growth is largely attributed to the increasing prevalence of urinary tract infections, rising cases of benign prostatic hyperplasia, growing awareness of sexual health, a rising aging population, and the rising incidence of chronic kidney diseases.

    The genitourinary drugs market is projected to experience consistent growth in the coming years. By 2029, its value is expected to reach $34.76 billion, growing at a compound annual growth rate (CAGR) of 2.9%. This expansion throughout the forecast period is attributed to several factors, including the increasing prevalence of urinary tract infections, a rising awareness of sexual health, the expansion of healthcare infrastructure, a greater demand for hormone replacement therapies, and the growing use of oral contraceptives. Significant trends during this period are anticipated to involve advancements in drug formulations and delivery systems, the integration of digital health solutions, technology-driven personalized medicine approaches, developments in biologic therapies, and progress in precision medicine.

    Unlock Your Free Sample Report for Exclusive Market Data:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24548&type=smp

    What Are The Key Drivers Of Growth In The Genitourinary Drugs Market?

    The increasing occurrence of genitourinary conditions is anticipated to drive expansion in the genitourinary drugs market in the future. These disorders are medical conditions impacting the genitourinary system, which includes both the urinary and reproductive organs, encompassing infections, cancers, and functional or structural issues. The rising prevalence of genitourinary disorders is attributed to an aging demographic, as age-related changes heighten the risk of urinary and reproductive health concerns. Genitourinary medications aid in managing these disorders by targeting conditions of the urinary and reproductive systems, offering relief from infections, inflammation, and dysfunction. They improve patient outcomes by facilitating effective, convenient, and condition-specific treatment, thereby enhancing overall quality of life. For instance, in April 2024, a report by the American Cancer Society, a US-based non-profit organization, stated that approximately 20 million new cancer cases were diagnosed globally in 2022, with 9.7 million deaths, and the number of cancer cases is projected to rise to 35 million by 2050. Consequently, the expanding prevalence of genitourinary disorders is fueling the growth of the genitourinary drugs market.

    What Are The Major Segment Types Covered In The Genitourinary Drugs Market?

    The genitourinary drugs market covered in this report is segmented –

    1) By Product: Urologicals, Hormonal Therapy, Gynecological, Anti-Infectives, Other Products

    2) By Route Of Administration: Oral, Parenteral, Topical

    3) By Application: Urinary Tract Infections (UTIs), Benign Prostatic Hyperplasia (BPH), Prostate Cancer, Overactive Bladder, Bladder Cancer, Other Applications

    4) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies

    Subsegments:

    1) By Urologicals: Benign Prostatic Hyperplasia (BPH) Drugs, Urinary Incontinence Drugs, Overactive Bladder (OAB) Drugs, Urolithiasis (Kidney Stone) Drugs, Erectile Dysfunction Drugs

    2) By Hormonal Therapy: Estrogen Therapy, Progestin Therapy, Gonadotropin-Releasing Hormone (GnRH) Agonists/Antagonists, Androgen Replacement Therapy, Selective Estrogen Receptor Modulators (SERMs)

    3) By Gynecological: Contraceptives, Menopausal Hormone Therapy, Fertility Drugs, Drugs for Endometriosis, Drugs for Polycystic Ovary Syndrome (PCOS)

    4) By Anti-Infectives: Urinary Tract Infection (UTI) Drugs, Sexually Transmitted Infection (STI) Drugs, Vaginal Antifungals, Antivirals

    5) By Other Products: Drugs for Chronic Pelvic Pain, Bladder Cancer Therapies, Interstitial Cystitis Drugs, Pelvic Organ Prolapse Treatment Drugs, Adjunctive Therapies

    How Are Trends Influencing The Genitourinary Drugs Market?

    Leading companies operating in the genitourinary drugs market are concentrating on developing innovative products, such as oral antibiotics, to enhance treatment convenience, improve patient adherence, and effectively combat infections. Oral antibiotics are antibacterial medications taken by mouth to treat infections caused by bacteria. For instance, in March 2025, GSK plc, a UK-based pharmaceutical company, received approval from the US Food and Drug Administration (FDA) for Blujepa (gepotidacin) for treating uncomplicated urinary tract infections caused by susceptible bacteria in women and girls aged 12 and older. This novel, first-in-class oral antibiotic operates by inhibiting bacterial DNA replication, targeting two critical enzymes: DNA gyrase and topoisomerase IV. Unlike traditional antibiotics, it binds to unique sites to overcome resistance, providing a targeted mechanism with improved safety and efficacy.

    Which Leading Companies Dominate The Genitourinary Drugs Market Share?

    Major companies operating in the genitourinary drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca plc, Abbott Laboratories, GSK plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Ipsen Société Anonyme, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals Public Limited Company, Zydus Lifesciences Limited, Endo International Public Limited Company, Takeda Pharmaceutical Company Limited, Zydus Lifesciences Limited, Melinta Therapeutics Inc., Asieris Pharmaceuticals, Sun Pharmaceutical Industries Ltd.

    Download The Full Report For Exclusive Market Findings:

    https://www.thebusinessresearchcompany.com/report/genitourinary-drugs-global-market-report

    Which Geographies Are Emerging As Strong Markets For The Genitourinary Drugs Industry?

    North America was the largest region in the genitourinary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genitourinary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request A Customized Version Of The Genitourinary Drugs Market Report:

    https://www.thebusinessresearchcompany.com/customise?id=24548&type=smp

    Browse Through More Reports Similar to the Global Genitourinary Drugs Market 2025, By The Business Research Company

    Genito Urinary Drugs Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/genito-urinary-drugs-global-market-report

    Generic Oncology Drugs Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/generic-oncology-drugs-global-market-report

    Pharmaceutical Label Global Market Report 2025

    https://www.thebusinessresearchcompany.com/report/pharmaceutical-label-global-market-report

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Global Genitourinary Drugs Market Landscape: Trends and Market Share to 2029

    Global Genitourinary Drugs Market Landscape: Trends and Market Share to 2029

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    How Will the Genitourinary Drugs Market Evolve in Terms of Growth and Size by 2029?

    The market size of genitourinary drugs has exhibited consistent growth in the past few years. Its projected growth is from $30.07 billion in 2024 to $31.02 billion in 2025, with a compound annual growth rate (CAGR) of 3.2%. Factors contributing to this historic period growth include an increased incidence of urinary tract infections, a surge in benign prostatic hyperplasia cases, heightened awareness about sexual health, a growing elderly population, and the escalating incidences of chronic kidney diseases.

    Stable growth is anticipated in the genitourinary drugs market in the ensuing years, with its size predicted to reach $34.76 billion in 2029, exhibiting a compound annual growth rate (CAGR) of 2.9%. The upturn in the forecast period is due to the rising incidence of urinary tract infections, heightened knowledge around sexual health, improving healthcare structure, escalating demand for hormone replacement treatments, and an increase in the consumption of oral contraceptives. The forecast period also signifies key trends such as enhancements in drug formulations and delivery systems, incorporation of digital health solutions, personalized medicine approaches fueled by technology, progression in biologic therapies, and breakthroughs in precision medicine.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24548&type=smp

    What factors are expected to fuel Genitourinary Drugs market growth in the coming years?

    The genitourinary drugs market is projected to expand due to the increasing incidence of genitourinary disorders. Medical conditions impacting the urinary and reproductive organs, such as infections, cancers, and functional or structural problems, are classified as genitourinary disorders. A rise in these disorders is primarily as a result of an aging population, which is more susceptible to urinary and reproductive health concerns. Genitourinary drugs are designed to target conditions of the urinary and reproductive system, providing a respite from infections, inflammation, and dysfunctions. These drugs enhance the quality of life by supporting effective, convenient, and specific treatments, thus improving patient outcomes. For instance, the American Cancer Society released a report in April 2024 stating that roughly 20 million new cancer cases were diagnosed worldwide in 2022, causing approximately 9.7 million deaths. The report further indicates that cancer cases are expected to surge, reaching an estimate of 35 million by 2050. Therefore, the escalating incidence of genitourinary disorders is pushing the growth of the genitourinary drugs market.

    What Are The Key Findings From The Segmentation Analysis Of The Genitourinary Drugs Market?

    The genitourinary drugs market covered in this report is segmented –

    1) By Product: Urologicals, Hormonal Therapy, Gynecological, Anti-Infectives, Other Products

    2) By Route Of Administration: Oral, Parenteral, Topical

    3) By Application: Urinary Tract Infections (UTIs), Benign Prostatic Hyperplasia (BPH), Prostate Cancer, Overactive Bladder, Bladder Cancer, Other Applications

    4) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies

    Subsegments:

    1) By Urologicals: Benign Prostatic Hyperplasia (BPH) Drugs, Urinary Incontinence Drugs, Overactive Bladder (OAB) Drugs, Urolithiasis (Kidney Stone) Drugs, Erectile Dysfunction Drugs

    2) By Hormonal Therapy: Estrogen Therapy, Progestin Therapy, Gonadotropin-Releasing Hormone (GnRH) Agonists/Antagonists, Androgen Replacement Therapy, Selective Estrogen Receptor Modulators (SERMs)

    3) By Gynecological: Contraceptives, Menopausal Hormone Therapy, Fertility Drugs, Drugs for Endometriosis, Drugs for Polycystic Ovary Syndrome (PCOS)

    4) By Anti-Infectives: Urinary Tract Infection (UTI) Drugs, Sexually Transmitted Infection (STI) Drugs, Vaginal Antifungals, Antivirals

    5) By Other Products: Drugs for Chronic Pelvic Pain, Bladder Cancer Therapies, Interstitial Cystitis Drugs, Pelvic Organ Prolapse Treatment Drugs, Adjunctive Therapies

    Which Trends Are Expected To Shape The Future Of The Genitourinary Drugs Market?

    Leading entities in the genitourinary drugs market are centering their efforts on the creation of innovative products like oral antibiotics. These products aim to augment treatment convenience, amplify patient adherence, and efficiently handle infections. Oral antibiotics are antimicrobial drugs consumed orally to counteract bacterial infections. In one significant development, GSK plc, a pharmaceutical firm from the UK, acquired approval for Blujepa (gepotidacin) from the US Food and Drug Administration (FDA) in March 2025. This medication is designed to treat uncomplicated urinary tract infections instigated by susceptible bacteria in females and girls aged 12 and above. Blujepa marks an original, inaugural oral antibiotic that impedes bacterial DNA replication by aiming at two vital enzymes, DNA gyrase, and topoisomerase IV. Diverging from traditional antibiotics, it latches onto unique sites to surmount resistance, providing a specified mechanism with elevated safety and effectiveness.

    What Are The Most Active Companies In The Genitourinary Drugs Market Today?

    Major companies operating in the genitourinary drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca plc, Abbott Laboratories, GSK plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Ipsen Société Anonyme, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals Public Limited Company, Zydus Lifesciences Limited, Endo International Public Limited Company, Takeda Pharmaceutical Company Limited, Zydus Lifesciences Limited, Melinta Therapeutics Inc., Asieris Pharmaceuticals, Sun Pharmaceutical Industries Ltd.

    Get The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/genitourinary-drugs-global-market-report

    Which Regional Markets Are Attracting The Most Investment In Genitourinary Drugs?

    North America was the largest region in the genitourinary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genitourinary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=24548&type=smp

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Strategic Report on Lateral Epicondylitis Treatment Market: Growth Opportunities and Emerging Challenges

    Strategic Report on Lateral Epicondylitis Treatment Market: Growth Opportunities and Emerging Challenges

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    What CAGR Is Anticipated for the Lateral Epicondylitis Treatment Market Through 2029?

    The market for lateral epicondylitis treatment has experienced robust growth in the past few years. The market size, which stands at $2.22 billion in 2024, is expected to expand to a worth of $2.34 billion in 2025, showcasing a compound annual growth rate (CAGR) of 5.4%. This past growth can be attributed to several factors such as a rise in the number of lateral epicondylitis cases, an aging population susceptible to musculoskeletal disorders, a higher incident rate in athletes and manual workers, increased knowledge about repetitive strain injuries, and the sedentary urban lifestyle which often leads to muscle or joint strain.

    The market for lateral epicondylitis treatment is forecasted to undergo significant growth in the coming years, with a projected value of $2.84 billion in 2029, reflecting a compound annual growth rate (CAGR) of 5.0%. This growth during the forecast period can be credited to factors such as increased participants in tennis and other racquet sports, escalating risks in construction and manufacturing jobs, increased disposable income allowing access to treatment, a broader network of physical therapy and orthopedic clinics, and the heightened importance of sports medicine departments. Prominent trends expected within the forecast period encompass innovation in unintrusive treatment options, the evolution of regenerative medicine, advancements in robotics-assisted physical therapy, the expansion of wearable rehabilitation devices, and the growth of AI-powered diagnostics and personalized treatment.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24585&type=smp

    What Market Forces Are Driving The Lateral Epicondylitis Treatment Sector In 2025 And Beyond?

    The advancement in the lateral epicondylitis treatment market is anticipated to be propelled by the rise in sports and physical activities. Sports and physical activities, whether structured or recreational, involve specific bodily movements aimed at enhancing physical fitness, preserving health, or participating in competitive or leisurely activities. This increase in active pursuits is a result of heightened health consciousness, with an emphasis on fitness to stave off illnesses and bolster physical and mental well-being. Lateral epicondylitis treatment aids sports and physical activities as it helps regain painless arm function, enabling individuals to execute actions like gripping and swinging without discomfort or hindrance. For example, the US-based trade association, the Sports and Fitness Industry Association (SFIA), shared in February 2024 that there was a 2.2% increase from the previous year in physical activity participation, with 78.8% of Americans, or 242 million people, engaging in at least one physical activity in 2023. Thus, the increase in sports and physical activities is fueling the progression of the lateral epicondylitis treatment market.

    How Is The Global Lateral Epicondylitis Treatment Market Categorized By Segments?

    The lateral epicondylitis treatment market covered in this report is segmented –

    1) By Treatment Type: Non-Surgical Treatment, Surgical Treatment

    2) By Age Group: Pediatric, Adult, Geriatric

    3) By Application: Athlete, Other Applications

    4) By End Use: Hospitals, Ambulatory Surgical Centers, Orthopedic Clinics, Homecare Settings, Other End Uses

    Subsegments:

    1) By Non-Surgical Treatment: Physical Therapy, Pharmacological Therapy, Orthotic Devices, Injections

    2) By Surgical Treatment: Open Surgery, Arthroscopic Surgery

    What Long-Term Trends Are Likely To Affect The Lateral Epicondylitis Treatment Market?

    Major firms involved in the lateral epicondylitis treatment market are working on creating new and innovative treatments, including plasma therapies. These new techniques aim to widen the scope of treatments available and provide advanced, non-surgical alternatives for patients with orthopedic ailments. Plasma therapies use elements of blood plasma, particularly antibodies or growth factors, in assisting the body’s healing processes and treating a variety of medical conditions. For example, Tree Top Hospital (TTH), a high-tech medical facility based in the Maldives, launched its platelet-rich plasma (PRP) treatments, a significant addition to its advanced orthopedic care services, in December 2023. This ground-breaking therapy uses the body’s natural ability to heal to address specific musculoskeletal issues like lateral epicondylitis (also known as tennis elbow), initial-stage knee arthritis, and tendon injuries associated with sports. TTH’s goal with the introduction of PRP therapy is to boost patient recovery with minimally invasive, scientifically supported regenerative treatments, reducing the reliance on surgical procedures.

    Which Firms Are Considered Leaders In The Lateral Epicondylitis Treatment Market Space?

    Major companies operating in the lateral epicondylitis treatment market are Merck & Co. Inc., 3M Company, Mayo Foundation for Medical Education and Research (MFMER), Cleveland Clinic, Chugai Pharmaceutical, Johns Hopkins Medicine, MedStar Health, Cipla Inc., Enovis Corporation, OttoBock HealthCare, Ossur Corporate, Max Healthcare, Seikagaku Corporation, Texas Orthopedic Specialists, Johari Digital, Mediheal Group of Hospitals, Scandinavian Physiotherapy Center, Veritas Health LLC, Folsom Orthopaedics & Sports Medicine, ReLiva Physiotherapy & Rehab, Molecular Pharmacology Limited

    Get The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/lateral-epicondylitis-treatment-global-market-report

    What Role Do Regional Policies And Investments Play In Lateral Epicondylitis Treatment Market Expansion?

    North America was the largest region in the lateral epicondylitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lateral epicondylitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=24585&type=smp

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Asia +44 7882 955267 & +91 8897263534

    Europe +44 7882 955267

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Genitourinary Drugs Industry Insights 2025 – Market Forecast for Executives and Planners

    Genitourinary Drugs Industry Insights 2025 – Market Forecast for Executives and Planners

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    How Has the Genitourinary Drugs Market Size Changed, over the years?

    The market for genitourinary drugs has seen consistent expansion over the years. There is a projection for this market to increase from $30.07 billion in 2024 to $31.02 billion in 2025, with a compound annual growth rate (CAGR) of 3.2%. The previous growth in the market is attributed to factors such as a rise in urinary tract infection cases, increased instances of benign prostatic hyperplasia, a growing understanding of sexual health, an increase in the aging population, and an ever-increasing occurrence of chronic kidney diseases.

    How Much Will the Genitourinary Drugs Market Be Worth in 2029?

    In the coming years, the genitourinary drugs market is projected to experience consistent expansion, reaching a total value of $34.76 billion by 2029, with a compound annual growth rate (CAGR) of 2.9%. This growth trajectory during the forecast period could be a result of heightened occurrences of urinary tract infections, increased public consciousness of sexual health, a growing healthcare base, surging demand for hormone replacement treatments, and a rise in the use of oral contraceptives. The forecast period is also expected to witness a progression in drug formulations and delivery systems, the infusion of digital health solutions, personalized medicine backed by technology, innovations in biologic therapies, and breakthroughs in precision medicine.

    Download The Free Sample Report Here:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24548&type=smp

    Which is the Largest Company in the Genitourinary Drugs Market?

    Major companies operating in the genitourinary drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol Myers Squibb, AstraZeneca plc, Abbott Laboratories, GSK plc, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Ipsen Société Anonyme, Aurobindo Pharma Limited, Dr. Reddy’s Laboratories Limited, Cipla Limited, Hikma Pharmaceuticals Public Limited Company, Zydus Lifesciences Limited, Endo International Public Limited Company, Takeda Pharmaceutical Company Limited, Zydus Lifesciences Limited, Melinta Therapeutics Inc., Asieris Pharmaceuticals, Sun Pharmaceutical Industries Ltd.

    What Are the Main Market Drivers in the Genitourinary Drugs Industry?

    Anticipated growth in the genitourinary drugs market is attributed to the increase in genitourinary disorders. These medical conditions, which impact both the urinary and reproductive organs and include infections, cancers, and functional or structural illnesses, are seeing an uptick due to an aging population. This demographic change elevates the risk of urinary and reproductive health problems. Genitourinary drugs are critical in addressing these disorders as they alleviate symptoms of infections, inflammation, and dysfunction by targeting conditions in the urinary and reproductive system. They enhance the overall quality of life by providing effective, convenient, and disorder-specific treatment options which improve patient outcomes. For example, a report by the American Cancer Society in April 2024, a non-profit organization in the U.S., stated that an estimated 20 million new cancer cases were diagnosed globally in 2022, resulting in 9.7 million deaths, and this figure is predicted to surge to 35 million by 2050. Hence, the genitourinary drugs market is expanding due to the increasing incidence of genitourinary disorders.

    Request For A Customized Report:

    https://www.thebusinessresearchcompany.com/customise?id=24548&type=smp

    How Is the Genitourinary Drugs Market Segments Structured?

    The genitourinary drugs market covered in this report is segmented –

    1) By Product: Urologicals, Hormonal Therapy, Gynecological, Anti-Infectives, Other Products

    2) By Route Of Administration: Oral, Parenteral, Topical

    3) By Application: Urinary Tract Infections (UTIs), Benign Prostatic Hyperplasia (BPH), Prostate Cancer, Overactive Bladder, Bladder Cancer, Other Applications

    4) By Distribution Channel: Hospital Pharmacies, Drug Store And Retail Pharmacies, Online Pharmacies

    Subsegments:

    1) By Urologicals: Benign Prostatic Hyperplasia (BPH) Drugs, Urinary Incontinence Drugs, Overactive Bladder (OAB) Drugs, Urolithiasis (Kidney Stone) Drugs, Erectile Dysfunction Drugs

    2) By Hormonal Therapy: Estrogen Therapy, Progestin Therapy, Gonadotropin-Releasing Hormone (GnRH) Agonists/Antagonists, Androgen Replacement Therapy, Selective Estrogen Receptor Modulators (SERMs)

    3) By Gynecological: Contraceptives, Menopausal Hormone Therapy, Fertility Drugs, Drugs for Endometriosis, Drugs for Polycystic Ovary Syndrome (PCOS)

    4) By Anti-Infectives: Urinary Tract Infection (UTI) Drugs, Sexually Transmitted Infection (STI) Drugs, Vaginal Antifungals, Antivirals

    5) By Other Products: Drugs for Chronic Pelvic Pain, Bladder Cancer Therapies, Interstitial Cystitis Drugs, Pelvic Organ Prolapse Treatment Drugs, Adjunctive Therapies

    What Strategic Trends Are Transforming the Genitourinary Drugs Market?

    Prominent players in the genitourinary drugs market are prioritizing the development of cutting-edge products such as oral antibiotics. These companies aim to amplify treatment ease, bolster patient compliance, and effectively tackle infections. Oral antibiotics are antibacterial medication administered orally to deal with bacterial infections. As an illustration, GSK plc, a global pharmaceutical organization headquartered in the UK, obtained endorsement from the US Food and Drug Administration (FDA) in March 2025 for Blujepa (gepotidacin). The approved medication is designed for the treatment of uncomplicated urinary tract infections brought about by susceptible bacteria in females and girls aged 12 and older. Blujepa is an innovative, pioneer oral antibiotic that functions by blocking bacterial DNA replication. It specifically targets two significant enzymes, DNA gyrase and topoisomerase IV. In comparison to conventional antibiotics, it adheres to unique sites to bypass resistance, thereby providing a specific mechanism with enhanced safety and effectiveness.

    Access The Full Report Here:

    https://www.thebusinessresearchcompany.com/report/genitourinary-drugs-global-market-report

    Which Global Regions Offer the Highest Growth in the Genitourinary Drugs Market?

    North America was the largest region in the genitourinary drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the genitourinary drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Purchase The Full Report Today:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24548

    This Report Delivers Insight On:

    1. How big is the genitourinary drugs market, and how is it changing globally?

    2. Who are the major companies in the genitourinary drugs market, and how are they performing?

    3. What are the key opportunities and risks in the genitourinary drugs market right now?

    4. Which products or customer segments are growing the most in the genitourinary drugs market?

    5. What factors are helping or slowing down the growth of the genitourinary drugs market?

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Lateral Epicondylitis Treatment Forecast Report – Designed for Decision Makers and Product Teams

    Lateral Epicondylitis Treatment Forecast Report – Designed for Decision Makers and Product Teams

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    #What Is the Growth Rate of the Lateral Epicondylitis Treatment Market?#_x000D_

    The market for treating lateral epicondylitis has experienced a robust growth in the last few years. Expanding from $2.22 billion in 2024, it is projected to reach $2.34 billion in 2025, a compound annual growth rate (CAGR) of 5.4%. This surge during the historical period can be due to several factors such as increasing instances of lateral epicondylitis, an older population susceptible to musculoskeletal conditions, higher occurrence in athletes and people doing manual work, raising awareness of repetitive strain injuries, along with the urban lifestyle leading to joint or muscle strain._x000D_

    _x000D_

    #What Growth Rate Is Forecasted for the Lateral Epicondylitis Treatment Market by 2029?#_x000D_

    The market size for the treatment of lateral epicondylitis is anticipated to experience significant expansion in the coming years, reaching approximately $2.84 billion in 2029, an increase characterized by a compound annual growth rate (CAGR) of 5.0%. This anticipated growth during the forecast period can be linked to various factors including an increase in people playing tennis and racquet sports, an uptick in workplace dangers in construction and manufacturing industries, higher disposable income leading to greater accessibility to treatments, a broader network of physical therapy and orthopedic clinics, and the growing influence of sports medicine departments. Noteworthy trends expected in the forecast period are the innovation in non-invasive treatment methods, the rise of regenerative medicine, advancements in robotic-assisted physiotherapy, the increasing market for wearable rehabilitation devices, and the use of AI in diagnostics and personalized treatment._x000D_

    _x000D_

    #Download The Free Sample Report Here:#_x000D_

    https://www.thebusinessresearchcompany.com/sample.aspx?id=24585&type=smp_x000D_

    _x000D_

    #Which Key Companies Are Shaping the Future of the Lateral Epicondylitis Treatment Market?#_x000D_

    Major companies operating in the lateral epicondylitis treatment market are Merck & Co. Inc., 3M Company, Mayo Foundation for Medical Education and Research (MFMER), Cleveland Clinic, Chugai Pharmaceutical, Johns Hopkins Medicine, MedStar Health, Cipla Inc., Enovis Corporation, OttoBock HealthCare, Ossur Corporate, Max Healthcare, Seikagaku Corporation, Texas Orthopedic Specialists, Johari Digital, Mediheal Group of Hospitals, Scandinavian Physiotherapy Center, Veritas Health LLC, Folsom Orthopaedics & Sports Medicine, ReLiva Physiotherapy & Rehab, Molecular Pharmacology Limited_x000D_

    _x000D_

    #Which Factors Are Driving Demand in the Lateral Epicondylitis Treatment Industry?#_x000D_

    The rise in sports and physical pursuits is anticipated to boost advancements in the market for lateral epicondylitis treatment. Sports and physical activities consist of planned or leisure physical exertions made to enhance physical health, sustain wellness, or partake in competitive or recreational endeavors. Due to the surge in awareness of the importance of health, more individuals are focusing on fitness to ward off diseases and boost physical and mental wellness. Lateral epicondylitis treatment aids those involved in sports and physical activities by restoring painless arm movement, enabling individuals to execute actions like gripping and swinging without uneasiness or limitation. As an example, in February 2024 according to the Sports and Fitness Industry Association (SFIA), a trade association based in the US, reported that 78.8% of Americans, equivalent to 242 million people, engaged in at least one physical activity in 2023, representing a 2.2% increase from the previous year. Thus, the expansion in sports and physical pursuits is propelling the advancement of the lateral epicondylitis treatment market._x000D_

    _x000D_

    #Request For A Customized Report:#_x000D_

    https://www.thebusinessresearchcompany.com/customise?id=24585&type=smp_x000D_

    _x000D_

    #How Is the Lateral Epicondylitis Treatment Market Segmented by Several Divisions?#_x000D_

    The lateral epicondylitis treatment market covered in this report is segmented –_x000D_

    _x000D_

    1) By Treatment Type: Non-Surgical Treatment, Surgical Treatment_x000D_

    2) By Age Group: Pediatric, Adult, Geriatric_x000D_

    3) By Application: Athlete, Other Applications_x000D_

    4) By End Use: Hospitals, Ambulatory Surgical Centers, Orthopedic Clinics, Homecare Settings, Other End Uses_x000D_

    _x000D_

    Subsegments:_x000D_

    1) By Non-Surgical Treatment: Physical Therapy, Pharmacological Therapy, Orthotic Devices, Injections_x000D_

    2) By Surgical Treatment: Open Surgery, Arthroscopic Surgery_x000D_

    _x000D_

    #What are the Emerging Market Trends Driving the Growth of the Lateral Epicondylitis Treatment Industry?#_x000D_

    Leading businesses in the lateral epicondylitis treatment marketplace are concentrating their efforts on creating novel solutions, for example plasma therapies, that aim to broaden the spectrum of treatment alternatives and deliver advanced, non-surgical methods of care to patients suffering from orthopedic issues. Plasma therapies are procedures that utilize specific components of blood plasma, most notably antibodies or growth factors, in order to manage various medical ailments and aid the body’s recovery processes. For instance, Tree Top Hospital (TTH), a Maldives-based, cutting-edge hospital, initiated treatments utilizing platelet-rich plasma (PRP) in December 2023 as an integral part of their progressive orthopedic care offerings. This revolutionary therapy uses the body’s inherent healing attributes to treat certain musculoskeletal issues, such as lateral epicondylitis (commonly known as tennis elbow), initial stage knee arthritis, and injuries related to sports tendons. By implementing PRP therapy, TTH is aiming to boost patient recovery via minimally invasive regenerative solutions backed by scientific evidence, thereby minimizing reliance on surgical procedures._x000D_

    _x000D_

    #Access The Full Report Here:#_x000D_

    https://www.thebusinessresearchcompany.com/report/lateral-epicondylitis-treatment-global-market-report_x000D_

    _x000D_

    #Which Regions Are Driving Growth in the Lateral Epicondylitis Treatment Market?#_x000D_

    North America was the largest region in the lateral epicondylitis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lateral epicondylitis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

    _x000D_

    #Purchase The Full Report Today:#_x000D_

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24585_x000D_

    _x000D_

    #This Report Delivers Insight On: #_x000D_

    1. How big is the lateral epicondylitis treatment market, and how is it changing globally?_x000D_

    2. Who are the major companies in the lateral epicondylitis treatment market, and how are they performing?_x000D_

    3. What are the key opportunities and risks in the lateral epicondylitis treatment market right now?_x000D_

    4. Which products or customer segments are growing the most in the lateral epicondylitis treatment market?_x000D_

    5. What factors are helping or slowing down the growth of the lateral epicondylitis treatment market?_x000D_

    _x000D_

    #About The Business Research Company:#_x000D_

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game._x000D_

    _x000D_

    #Get in touch with us:#_x000D_

    The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

    Americas +1 3156230293_x000D_

    Asia +44 2071930708_x000D_

    Europe +44 2071930708_x000D_

    Email us at info@tbrc.info_x000D_

    _x000D_

    #Follow us on:#_x000D_

    _x000D_

    LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ_x000D_

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model